9 rezultatima
TECHNICAL FIELD
The present invention relates to methods of identifying candidate compounds for regulating skeletal muscle mass or function or regulating the activity or expression of a dopamine receptor (dopamine receptor). The invention also relates to methods for the treatment of skeletal muscle
FIELD OF THE INVENTION
This invention relates to methods and pharmaceutical compositions for regulating the levels of dopamine using a protein kinase C delta (PKCd) inhibitor. In particular, it relates to increasing the levels of dopamine in the central nervous systems (CNS) and in the treatment of
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of neurobiology and neurodegenerative diseases. More particularly, it-concerns the development of screening methods to detect and identify candidate molecules that confer neuroprotective
FIELD OF THE INVENTION
The subject invention relates to thiazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present
FIELD OF THE INVENTION
The subject invention relates to imidazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present
FIELD OF THE INVENTION
The subject invention relates to imidazole derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat abnormal cell growth and certain diseases and conditions of the central nervous system. The compounds of the present
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
This application is a U.S. National Stage Application under 35 U.S.C. .sctn. 371 of PCT Application No. PCT/KR2014/009289, filed Oct. 1, 2014, which claims priority to Korean Patent Application No. 10-2013-0118753, filed Oct. 4, 2013, whose entire
BACKGROUND
Idiopathic Parkinson's Disease (IPD) is a progressive neurodegenerative disorder. The onset of IPD symptoms begin to manifest when a threshold reduction of 60%-70% nigral neurons accompanied by an 80%-90% attenuation in striatal dopamine efflux, has been reached (Koller, W. C., "When does
FIELD OF THE INVENTION
The invention relates to the fields of molecular biology and medicine. More particularly, the invention relates to methods for treating neurodegenerative diseases including Parkinson's disease and stroke in mammalian subjects.
BACKGROUND
Neuronal death plays a critical role in